Market News / Story

New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026

GlobeNewswire ·

GlobeNewswire reports: Phase 2 results with daridorexant in pediatric insomnia disorder will be presented in a late-breaking "Impactful Clinical Trial" session. These are the first and only investigational data of a dual orexin receptor antagonist in children. A growing body of real-world evidence will examine the use of daridorexant in routine clinical practice, including sleep outcomes, daytime functioning, quality of life and work productivity. Further research will examine daridorexant…

VIEW SOURCE

Back to news